A Novel Drug Delivery Route for Treatment of Diabetic Macular Edema: Suprachoroidal Triamcinolone Acetonide Administration



To evaluate the safety, tolerability and efficacy of of suprachoroidal injection of triamcinolone acetonide (TA) for diabetic macular edema (DME).


Seventeen eyes of 17 patients were given suprachoroidal injection of 4mg TA for DME. Injection was performed with a 30G needle approximately 1mm length, 4mm from the limbus directly to the suprachoroidal space. The best corrected visual acuity (BCVA), central subfield thickness (CST), measured with optical coherence tomography (OCT) and intraocular pressure (IOP) were determined during the 12 weeks follow-up period.


17 individuals with DME were enrolled. Mean baseline CST was 645 m (SD±160). Subjects with ≥20 reduction in CST was 12(70%), CST >310 m was 10 (59%). All fifteen efficacy-evaluable subjects had improvements in visual acuity. Eight eyes had on average a greater than 2 line improvement in visual acuity through week 12. No serious ocular adverse events and no steroid-related increases in IOP were observed and no subjects required IOP-lowering medication.


Injection of TS to the suprachoroidal space in DME, was well tolerated without any serious ocular adverse events and produced significant resolution in CST and significant improvement in BCVA.



Murat Oncel
Istanbul, Turkey
Email : muratoncel@superonline.com
Cell Phone: +905309721245
Work Phone: +902122248471